The Medical Letter on Drugs and Therapeutics
Brexpiprazole (Rexulti) for Schizophrenia and Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD). Aripiprazole (Abilify), a structurally similar second-generation antipsychotic also comarketed by Otsuka (with BMS), recently became available generically.

STANDARD TREATMENT – Schizophrenia - Second-generation antipsychotics are not clearly more effective than first-generation drugs, but they have a much lower risk of tardive dyskinesia. Clozapine (Clozaril, and others) is the most effective second-generation antipsychotic drug, but it is usually reserved for refractory disease because of its potential for serious toxicity. Olanzapine (Zyprexa, and generics) appears to have slight advantages over some other drugs in efficacy, but its metabolic ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brexpiprazole (Rexulti) for Schizophrenia and Depression
Article code: 1475c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian